TCRT

Alaunos Therapeutics Inc. (TCRT) | Rumor.io

Alaunos Therapeutics

TCRT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,798

Bullish sentiment (50-day avg)84%

Price to earnings ratio-0.5

Market capitalization2.6M

Earnings per share-1.75

Dividend yield (TTM)—

Revenue (annual)5K

Net income (annual)-4.2M

Social

What share of all stock conversation is about TCRT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 18

$TCRT, Alaunos Therapeutics, Inc., rose 40% after patent news, reaching $3.14.
The stock needs to break the downtrend and reclaim $2.35 VWAP to turn around.
A registered direct offering of 380,469 shares and pre-funded warrants at $1.46 was announced, and a new US patent application was published for "IDENTIFICATION OF NEOANTIGEN-REACTIVE T CELL RECEPTORS".

Generated by AI

Sentiment

Of the messages about TCRT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	95.65% +14.88	80.95% -7.76	89.92% +14.67
Bearish	—	4.35% -14.88	19.05% +7.76	10.08% -14.67

Bullish· Oct 9

$TCRT has broken through resistance on high volume, with a strong follow-through and momentum intact, suggesting a potential continuation of its upward trend.
The stock has a clean breakout from a bull pennant, with strong volume and follow-through after holding consolidation above $6, indicating a bullish technical setup.
$TCRT has significant upside potential, with a forecasted 10-20% increase in price, driven by regaining Nasdaq compliance, new funding for its obesity program, and a recovery in the biotech market.

Bearish· Apr 3

The author believes $TCRT has reversed and will dump back under $3 by tomorrow.
The stock may be a "pump and dump" scheme with no underlying value, and its current price is not backed by any substantial news.
The author thinks the company is struggling financially, being "neg cash" and possibly unable to produce a product, making it a short waiting to happen.

Generated by AI

Topics

Of the messages about TCRT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	10%	41.67%	53.13%
Technical Analysis	100%	80%	57.14%	41.49%
Controversies	0%	10%	1.19%	1.49%
Analysts	0%	0%	0%	3.88%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Nov 29

Alaunos Therapeutics, Inc. (TCRT) announced the pricing of a public offering of common stock.
TCRT expects to dose the next patient in its TCR-T Library Phase 1/2 trial in 4Q22, with early data from the trial presented in September 2022.
TCRT has commenced an underwritten public offering of its common stock, with the company's shares slumping 20% premarket.

Technical Analysis· Jun 9

$TCRT has shown a positive trajectory, with the shorts providing dips, and the 50ma on the 15 min chart providing a bounce.
The stock is displaying a Cup and Handle pattern on the 15 min chart, with the handle potentially breaking up and leading to a multi-week run.
The Ascending Triangle pattern is forming, with a price target of 11.16, and the stock has recently closed above the 50-day SMA.

Generated by AI

Community

Of the messages about TCRT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	68.75%	25.73%	67.22%
Newcomers	100%	31.25%	74.27%	32.78%

Regulars· Sep 18

$TCRT needs to see a significant increase in trading volume to reverse its downtrend, with the first step being to break the current downtrend and then reclaim the $2.35 VWAP.
The recent patent grant for "IDENTIFICATION OF NEOANTIGEN-REACTIVE T CELL RECEPTORS" may be a positive development for Alaunos Therapeutics, potentially supporting its stock price.
$TCRT's strong performance may lead to a potential offering from the company to raise capital, which could further impact the stock's price.

Newcomers· Sep 18

Newcomers are shorting TCRT due to concerns about pump-and-dump catalysts in small caps.
The stock's recent price movement is attributed to a registered direct offering of 380,469 shares and pre-funded warrants at $1.46.
TCRT's price has been affected by a recent patent-related news event, with some traders eyeing potential IP-related filings or announcements.

Generated by AI

Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT) shares increased

11d agoBenzinga

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

12d agoBenzinga

Alaunos Therapeutics (TCRT) Stock Soars Over 29% After-Hours: Here's What's Going On

12d agoBenzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

12d agoBenzinga

Also Discussed

Investors talking about TCRT also mention

#	Name	Attention
1	Precigen Inc.PGEN	0%+0
2	Calithera Biosciences Inc.CALA	0%0
3	iShares Biotechnology ETFIBB	0.01%0
4	Halozyme Therapeutics Inc.HALO	0%0
5	Theriva Biologics, Inc.TOVX	0%0
6	Cellectis S.A. ADRCLLS	0%new
7	BLCM - Bellicum Pharmaceuticals, Inc.	——
8	BLUE - bluebird bio, Inc.	——
9	EGRX - Eagle Pharmaceuticals, Inc.	——
10	CNCR - Loncar Cancer Immunotherapy ETF	——

Alaunos Therapeutics Inc.

Healthcare
Biotechnology

Alaunos Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for cancer and metabolic disease. Its current portfolio includes clinical-stage and preclinical programs centered on engineered T-cell receptor approaches for solid tumors, along with oral small-molecule candidates for obesity and related metabolic disorders. The company’s oncology work is aimed at addressing difficult-to-treat cancers through immune-based technologies such as TCR-T cell therapies and proprietary discovery platforms for identifying tumor-specific targets. In metabolic health, Alaunos Therapeutics Inc. is developing non-incretin oral compounds designed to offer an alternative therapeutic approach for obesity and associated conditions. Headquartered in Fort Lauderdale, Florida, and founded in 2003, Alaunos Therapeutics Inc. operates in the biotechnology sector and primarily supports its business through research and development activities.

Website

Location

501 E. Las Olas Blvd.

Fort Lauderdale, FL, 33301

United States

Social

What share of all stock conversation is about TCRT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 18

$TCRT, Alaunos Therapeutics, Inc., rose 40% after patent news, reaching $3.14.
The stock needs to break the downtrend and reclaim $2.35 VWAP to turn around.
A registered direct offering of 380,469 shares and pre-funded warrants at $1.46 was announced, and a new US patent application was published for "IDENTIFICATION OF NEOANTIGEN-REACTIVE T CELL RECEPTORS".

Generated by AI

Sentiment

Of the messages about TCRT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	95.65% +14.88	80.95% -7.76	89.92% +14.67
Bearish	—	4.35% -14.88	19.05% +7.76	10.08% -14.67

Bullish· Oct 9

$TCRT has broken through resistance on high volume, with a strong follow-through and momentum intact, suggesting a potential continuation of its upward trend.
The stock has a clean breakout from a bull pennant, with strong volume and follow-through after holding consolidation above $6, indicating a bullish technical setup.
$TCRT has significant upside potential, with a forecasted 10-20% increase in price, driven by regaining Nasdaq compliance, new funding for its obesity program, and a recovery in the biotech market.

Bearish· Apr 3

The author believes $TCRT has reversed and will dump back under $3 by tomorrow.
The stock may be a "pump and dump" scheme with no underlying value, and its current price is not backed by any substantial news.
The author thinks the company is struggling financially, being "neg cash" and possibly unable to produce a product, making it a short waiting to happen.

Generated by AI

Topics

Of the messages about TCRT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	10%	41.67%	53.13%
Technical Analysis	100%	80%	57.14%	41.49%
Controversies	0%	10%	1.19%	1.49%
Analysts	0%	0%	0%	3.88%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Nov 29

Alaunos Therapeutics, Inc. (TCRT) announced the pricing of a public offering of common stock.
TCRT expects to dose the next patient in its TCR-T Library Phase 1/2 trial in 4Q22, with early data from the trial presented in September 2022.
TCRT has commenced an underwritten public offering of its common stock, with the company's shares slumping 20% premarket.

Technical Analysis· Jun 9

$TCRT has shown a positive trajectory, with the shorts providing dips, and the 50ma on the 15 min chart providing a bounce.
The stock is displaying a Cup and Handle pattern on the 15 min chart, with the handle potentially breaking up and leading to a multi-week run.
The Ascending Triangle pattern is forming, with a price target of 11.16, and the stock has recently closed above the 50-day SMA.

Generated by AI

Community

Of the messages about TCRT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	68.75%	25.73%	67.22%
Newcomers	100%	31.25%	74.27%	32.78%

Regulars· Sep 18

$TCRT needs to see a significant increase in trading volume to reverse its downtrend, with the first step being to break the current downtrend and then reclaim the $2.35 VWAP.
The recent patent grant for "IDENTIFICATION OF NEOANTIGEN-REACTIVE T CELL RECEPTORS" may be a positive development for Alaunos Therapeutics, potentially supporting its stock price.
$TCRT's strong performance may lead to a potential offering from the company to raise capital, which could further impact the stock's price.

Newcomers· Sep 18

Newcomers are shorting TCRT due to concerns about pump-and-dump catalysts in small caps.
The stock's recent price movement is attributed to a registered direct offering of 380,469 shares and pre-funded warrants at $1.46.
TCRT's price has been affected by a recent patent-related news event, with some traders eyeing potential IP-related filings or announcements.

Generated by AI

Alaunos Therapeutics

Social

Sep 18

Sentiment

Bullish· Oct 9

Bearish· Apr 3

Topics

Announcements· Nov 29

Technical Analysis· Jun 9

Community

Regulars· Sep 18

Newcomers· Sep 18

News

Alaunos Therapeutics raises $1.12M in registered direct offering

12 Health Care Stocks Moving In Friday's Pre-Market Session - IM Cannabis (NASDAQ:IMCC), Alaunos Therapeu

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Alaunos Therapeutics (TCRT) Stock Soars Over 29% After-Hours: Here's What's Going On

12 Health Care Stocks Moving In Thursday's After-Market Session

Also Discussed

Alaunos Therapeutics Inc.

Company Information

Location

News

Alaunos Therapeutics raises $1.12M in registered direct offering

12 Health Care Stocks Moving In Friday's Pre-Market Session - IM Cannabis (NASDAQ:IMCC), Alaunos Therapeu

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Alaunos Therapeutics (TCRT) Stock Soars Over 29% After-Hours: Here's What's Going On

12 Health Care Stocks Moving In Thursday's After-Market Session

Also Discussed

Social

Sep 18

Sentiment

Bullish· Oct 9

Bearish· Apr 3

Topics

Announcements· Nov 29

Technical Analysis· Jun 9

Community

Regulars· Sep 18

Newcomers· Sep 18